ApprovedFDA approval

Decnupaz (pivekimab sunirine-pvzy)

AbbVie (ABBV)

Marketer take

A CD123-targeted option in BPDCN, an ultra-rare blood cancer where Elzonris was the only approved drug, so the audience is tiny and concentrated in academic hematology centers.

Sponsor company
AbbVie (ABBV)
Indication
To treat adults with blastic plasmacytoid dendritic cell neoplasm
Therapeutic area
Oncology, Hematology
Event
FDA approval
Date
May 27, 2026
Status
Approved
Source
FDA page
Last verified
Nov 15, 2026

Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?

Get alerts when FDA dates move